EUVIMEDEUVIMED entdecken
Crossref

Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely

Yanai Hidekatsu

The Open Diabetes Journal · 2011

DOI: 10.2174/1876524601104010001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Open Diabetes Journal, 2011. Verfasst von Yanai Hidekatsu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the inactivation of glucagon-like peptide-1 (GLP-1).This protein, released from the gut following ingestion of a meal, stimulates insulin secretion and inhibits glucagon secretion.Compared with other anti-diabetic drugs, the pharmacological characteristics of DDP-4 inhibitor include improvement in postprandial hyperglycemia, low frequency of hypoglycemia, prevention of development of obesity, few adverse events.Taking account of pharmacological characteristic and our therapeutic experiences with DPP-4 inhibitor, we believe that DPP-4 inhibitor may be a useful and safe oral anti-diabetic drug for diabetes in the elderly people, diabetes complicated with obesity, chronic hepatitis/liver cirrhosis, and steroid-induced diabetes.

Zitieren

APA

Hidekatsu, Y. (2011). Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely. The Open Diabetes Journal. https://doi.org/10.2174/1876524601104010001

Vancouver

Hidekatsu Y. Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely. The Open Diabetes Journal. 2011. doi:10.2174/1876524601104010001

BibTeX
@article{Hidekatsu2011,
  author = {Hidekatsu, Yanai},
  title = {Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely},
  journal = {The Open Diabetes Journal},
  year = {2011},
  doi = {10.2174/1876524601104010001}
}
Kostenlos starten →